Q4: +4% org. sales growth, 39% adj. EBITA growth, strong cash flow '25e-'26e adj.
Redeye comments on Fable Media Group’s Q4 results, which were in line with expectations.
Minor estimate revisions due to M&A contribution Utilisation trend is positive '25e EV/EBITA of 8x, ...
'25e-'26e adj. EBITA down 3% Latent working capital release likely in Q1'25 '25e EV/EBITA of 9x is ~...
Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity on...
Redeye comments on Better Collective’s Q4-results and given the preannounced revenue and EBITDA outc...
Redeye updates on Raketech following the company’s Q4 report where we have lowered our growth foreca...
Redeye comments on Th1ng’s latest turmoil—shareholder revolt, board shake-up, and the founder’s ret...
Redeye updates its estimates following Surgical Science’s Q4 2024 report.
Redeye remains positive to Nekkar’s on the back of a Q4’24 report that beat our forecast, mainly dri...
Solid Q4 in light of headwinds, FX revaluations boost margin We push 5% EE growth from '25e to 26e, ...
Redeye strengthens its positive view of Avensia following an overall solid Q4 report.
Redeye provides its initial take on OEM’s Q4 2024 report, which came in above our estimates.
Medicinteknikbolaget iZafe Group rapporterade i linje med vår prognos.
Redeye comments on Avensia’s Q4 report, showing solid growth and cash flow but an adjusted EBIT some...
Weaker Q4 than we expected, on higher opex, but ACV was strong We cut '25e-'26e adj.
Fjärde kvartalet utvecklades svagare än vad både Cell Impact och vi förväntade oss.
Sales +3%, adj. EBITA +34%, +4% org. growth '25e-'26e EBITA estimates to increase by 5-10% Share to ...
Redeye leaves a comment following Alzinova’s announced study data form the high-dose phase Ib extens...
Sales in line with cons, adj. EBITA -7% vs cons Consensus EBITA estimate revisions slightly negative...
